The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: Possible therapeutic implications

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 2, 2014, Pages 322-337

  Zemva, Johanna ^a   Schubert, Markus ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SCIVIAS Hospital St Josef Internal Medicine   (Germany)

Author keywords

Alzheimer's disease; Amyloid; Diabetes mellitus; Insulin receptor; Insulin receptor substrates; Insulin like growth factor 1 receptor; Tau

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN [1-40]; AMYLOID BETA PROTEIN [1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; IBUTAMOREN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; ROSIGLITAZONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; COGNITION; ENZYMATIC DEGRADATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; MEMORY; NERVE CELL PLASTICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVE CELL;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR TARGETED THERAPY; NEURONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84907861812     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660141     Document Type: Article

References (242)

1. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53(9): 1937-1942.
2. Moloney AM, Griffin RJ, Timmons S, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010; 31(2): 224-243.
3. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122(4): 1316-1338.
4. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 2006; 313(5793): 1604-1610.
5. Freude S, Hettich MM, Schumann C, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J 2009; 23(10): 3315-3324.
6. Cohen E, Paulsson JF, Blinder P, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009; 139(6): 1157-1169.
7. Killick R, Scales G, Leroy K, et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 2009; 386(1): 257-262.
8. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69(1): 29-38.
9. Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008; 71(21): 1702-1708.
10. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010; 30(2): 131-146.
11. Long-Smith CM, Manning S, McClean PL, et al. The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-beta Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease. Neuromolecular Med 2013; 15(1): 102-114.
12. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's diseaseassociated Abeta oligomers. J Clin Invest 2012; 122(4): 1339-1353.
13. Van Obberghen E, Ksauga M, Le Cam A, et al. Biosynthetic labeling of insulin receptor: studies of subunits in cultured human IM-9 lymphocytes. Proc Natl Acad Sci USA 1981; 78(2): 1052-1056.
14. Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985; 313(6005): 756-761.
15. Chou CK, Dull TJ, Russell DS, et al. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 1987; 262(4): 1842-1847.
16. Kasuga M, Fujita-Yamaguchi Y, Blithe DL, Kahn CR. Tyrosinespecific protein kinase activity is associated with the purified insulin receptor. Proc Natl Acad Sci USA 1983; 80(8): 2137-2141.
17. White MF, Livingston JN, Backer JM, et al. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell 1988; 54(5): 641-649.
18. Seino S, Bell GI. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 1989; 159(1): 312-316.
19. McClain DA. Different ligand affinities of the two human insulin receptor splice variants are reflected in parallel changes in sensitivity for insulin action. Mol Endocrinol 1991; 5(5): 734-9.
20. Moller DE, Yokota A, Caro JF, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 1989; 3(8): 1263-9.
21. Goldstein BJ, Kahn CR. Analysis of mRNA heterogeneity by ribonuclease H mapping: application to the insulin receptor. Biochem Biophys Res Commun 1989; 159(2): 664-9.
22. Mosthaf L, Grako K, Dull TJ, et al. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 1990; 9(8): 2409-13.
23. Yamaguchi Y, Flier JS, Yokota A, et al. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 1991; 129(4): 2058-66.
24. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19(5): 3278-88.
25. Pandini G, Frasca F, Mineo R, et al. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277(42): 39684-95.
26. Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol 1997; 189(1): 33-48.
27. Sun XJ, Rothenberg P, Kahn CR, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991; 352(6330): 73-7.
28. Lavan BE, Fantin VR, Chang ET, et al. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem 1997; 272(34): 21403-7.
29. Lavan BE, Lane WS, Lienhard GE. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 1997; 272(17): 11439-43.
30. Uchida T, Myers MG Jr, White MF. IRS-4 mediates protein kinase B signaling during insulin stimulation without promoting antiapoptosis. Mol Cell Biol 2000; 20(1): 126-38.
31. Giovannone B, Scaldaferri ML, Federici M, et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev 2000; 16(6): 434-41.
32. Fruman DA, Rameh LE, Cantley LC. Phosphoinositide binding domains: embracing 3-phosphate. Cell 1999; 97(7): 817-20.
33. Yenush L, Zanella C, Uchida T, Bernal D, White MF. The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin. Mol Cell Biol 1998; 18(11): 6784-94.
34. Sawka-Verhelle D, Baron V, Mothe I, et al. Tyr624 and Tyr628 in insulin receptor substrate-2 mediate its association with the insulin receptor. J Biol Chem 1997; 272(26): 16414-20.
35. Sawka-Verhelle D, Tartare-Deckert S, White MF, Van Obberghen E. Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786. J Biol Chem 1996; 271(11): 5980-3.
36. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005; 87(1): 99-109.
37. Weigert C, Hennige AM, Brischmann T, et al. The phosphorylation of Ser318 of insulin receptor substrate 1 is not per se inhibitory in skeletal muscle cells but is necessary to trigger the attenuation of the insulin-stimulated signal. J Biol Chem 2005; 280(45): 37393-9.
38. Weigert C, Kron M, Kalbacher H, et al. Interplay and effects of temporal changes in the phosphorylation state of serine-302: -307: and -318 of insulin receptor substrate-1 on insulin action in skeletal muscle cells. Mol Endocrinol 2008; 22(12): 2729-40.
39. Herschkovitz A, Liu YF, Ilan E, et al. Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance. J Biol Chem 2007; 282(25): 18018-27.
40. Luo M, Langlais P, Yi Z, et al. Phosphorylation of human insulin receptor substrate-1 at Serine 629 plays a positive role in insulin signaling. Endocrinology 2007; 148(10): 4895-905.
41. Luo M, Reyna S, Wang L, et al. Identification of insulin receptor substrate 1 serine/threonine phosphorylation sites using mass spectrometry analysis: regulatory role of serine 1223. Endocrinology 2005; 146(10): 4410-6.
42. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 2009; 296(4): E581-91.
43. Gual P, Gremeaux T, Gonzalez T, et al. MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307: 612 and 632. Diabetologia 2003; 46(11): 1532-42.
44. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNKmediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci USA 2006; 103(44): 16454-9.
45. Sharfi H, Eldar-Finkelman H. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. Am J Physiol Endocrinol Metab 2008; 294(2): E307-15.
46. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283(3): E413-22.
47. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103(7): 931-43.
48. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005; 30(4): 194-204.
49. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998; 67: 481-507.
50. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15(23): 6541-51.
51. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114(PART 16): 2903-10.
52. Stokoe D, Stephens LR, Copeland T, et al. Dual role of phosphatidylinositol-3:4:5-trisphosphate in the activation of protein kinase B. Science 1997; 277(5325): 567-70.
53. Hresko RC, Murata H, Mueckler M. Phosphoinositide-dependent kinase-2 is a distinct protein kinase enriched in a novel cytoskeletal fraction associated with adipocyte plasma membranes. J Biol Chem 2003; 278(24): 21615-22.
54. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998; 8(1): 55-62.
55. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96(6): 857-68.
56. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005; 24(50): 7475-81.
57. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18(16): 1926-45.
58. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003; 278(18): 15461-4.
59. Oshiro N, Yoshino K, Hidayat S, et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004; 9(4): 359-66.
60. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9(1): 59-71.
61. Yang E, Zha J, Jockel J, et al. Bad, a heterodimeric partner for Bcl-XL and Bcl-2: displaces Bax and promotes cell death. Cell 1995; 80(2): 285-91.
62. Zha J, Harada H, Osipov K, et al. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem 1997; 272(39): 24101-4.
63. Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003; 23(18): 7084-92.
64. Partridge L, Bruning JC. Forkhead transcription factors and ageing. Oncogene 2008; 27(16): 2351-63.
65. Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992; 70(3): 431-42.
66. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351 Pt 2: 289-305.
67. Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signalregulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 1998; 18(5): 1633-41.
68. Hua LL, Zhao ML, Cosenza M, et al. Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNFalpha expression in human fetal astrocytes. J Neuroimmunol 2002; 126(1/2): 180-9.
69. Bhat NR, Feinstein DL, Shen Q, Bhat AN. p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells. Roles of nuclear factors, nuclear factor kappa B, cAMP response element-binding protein, CCAAT/enhancer-binding protein-beta, and activating transcription factor-2. J Biol Chem 2002; 277(33): 29584-92.
70. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003; 23(5): 1605-11.
71. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001; 76(1): 1-10.
72. Bolshakov VY, Carboni L, Cobb MH, Siegelbaum SA, Belardetti F. Dual MAP kinase pathways mediate opposing forms of longterm plasticity at CA3-CA1 synapses. Nat Neurosci 2000; 3(11): 1107-12.
73. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978; 272(5656): 827-9.
74. Werther GA, Hogg A, Oldfield BJ, et al. Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 1987; 121(4): 1562-70.
75. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991; 36(5): 343-62.
76. Unger J, McNeill TH, Moxley RT 3rd, et al. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 1989; 31(1): 143-57.
77. van Houten M, Posner BI. Insulin binds to brain blood vessels in vivo. Nature 1979; 282(5739): 623-5.
78. van Houten M, Posner BI. Specific binding and internalization of blood-borne [125I]-iodoinsulin by neurons of the rat area postrema. Endocrinology 1981; 109(3): 853-9.
79. Frank HJ, Jankovic-Vokes T, Pardridge WM, Morris WL. Enhanced insulin binding to blood-brain barrier in vivo and to brain microvessels in vitro in newborn rabbits. Diabetes 1985; 34(8): 728-33.
80. Duffy KR, Pardridge WM. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987; 420(1): 32-8.
81. Rotwein P, Burgess SK, Milbrandt JD, Krause JE. Differential expression of insulin-like growth factor genes in rat central nervous system. Proc Natl Acad Sci USA 1988; 85(1): 265-9.
82. Bondy CA, Werner H, Roberts CT Jr, LeRoith D. Cellular pattern of insulin-like growth factor-I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. Mol Endocrinol 1990; 4(9): 1386-98.
83. Bondy CA, Lee WH. Patterns of insulin-like growth factor and IGF receptor gene expression in the brain. Functional implications. Ann NY Acad Sci 1993; 692: 33-43.
84. Werther GA, Abate M, Hogg A, et al. Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridization-relationship to IGF-I receptors. Mol Endocrinol 1990; 4(5): 773-8.
85. Bondy C, Werner H, Roberts CT Jr, Le Roith D. Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience 1992; 46(4): 909-23.
86. Bohannon NJ, Corp ES, Wilcox BJ, et al. Characterization of insulin-like growth factor I receptors in the median eminence of the brain and their modulation by food restriction. Endocrinology 1988; 122(5): 1940-7.
87. Werther GA, Hogg A, Oldfield BJ, et al. Localization and Characterization of Insulin-Like Growth Factor-I Receptors in Rat Brain and Pituitary Gland Using in vitro Autoradiography and Computerized Densitometry* A Distinct Distribution from Insulin Receptors. J Neuroendocrinol 1989; 1(5): 369-77.
88. Matsuo K, Niwa M, Kurihara M, et al. Receptor autoradiographic analysis of insulin-like growth factor-I (IGF-I) binding sites in rat forebrain and pituitary gland. Cell Mol Neurobiol 1989; 9(3): 357-67.
89. Marks JL, Porte D Jr, Baskin DG. Localization of type I insulinlike growth factor receptor messenger RNA in the adult rat brain by in situ hybridization. Mol Endocrinol 1991; 5(8): 1158-68.
90. Margolis RU, Altszuler N. Insulin in the cerebrospinal fluid. Nature 1967; 215(5108): 1375-6.
91. Greco AV, Ghirlanda G, Fedeli G, Gambassi G. Insulin in the cerebro spinal fluid of man. Eur Neurol 1970; 3(5): 303-7.
92. Woods SC, Porte D Jr. Relationship between plasma and cerebrospinal fluid insulin levels of dogs. Am J Physiol 1977; 233(4): E331-4.
93. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 1997; 18(9): 1423-9.
94. Banks WA, Jaspan JB, Kastin AJ. Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 1997; 18(8): 1257-62.
95. Urayama A, Banks WA. Starvation and triglycerides reverse the obesity-induced impairment of insulin transport at the blood-brain barrier. Endocrinology 2008; 149(7): 3592-7.
96. Israel PA, Park CR, Schwartz MW, et al. Effect of diet-induced obesity and experimental hyperinsulinemia on insulin uptake into CSF of the rat. Brain Res Bull 1993; 30(5-6): 571-5.
97. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000; 49(9): 1525-33.
98. Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8(4): 555-67.
99. Wallum BJ, Taborsky GJ Jr, Porte D Jr, et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J Clin Endocrinol Metab 1987; 64(1): 190-4.
100. Schwartz MW, Figlewicz DF, Kahn SE, et al. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 1990; 11(3): 467-72.
101. Yu Y, Kastin AJ, Pan W. Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier. Endocrinology 2006; 147(6): 2611-5.
102. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5(6): 514-6.
103. Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism 1988; 37(2): 136-40.
104. Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology 2000; 72(3): 171-8.
105. Carro E, Nunez A, Busiguina S, Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 2000; 20(8): 2926-33.
106. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I. Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 2005; 25(47): 10884-93.
107. Nishijima T, Piriz J, Duflot S, et al. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 2010; 67(5): 834-46.
108. Huang SS, Ling TY, Tseng WF, et al. Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1. FASEB J 2003; 17(14): 2068-81.
109. Michaluk P, Kaczmarek L. Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. Cell Death Differ 2007; 14(7): 1255-8.
110. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3(6): 343-53.
111. Brief DJ, Davis JD. Reduction of food intake and body weight by chronic intraventricular insulin infusion. Brain Res Bull 1984; 12(5): 571-5.
112. Debons AF, Krimsky I, From A. A direct action of insulin on the hypothalamic satiety center. Am J Physiol 1970; 219(4): 938-43.
113. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289(5487): 2122-5.
114. Ajaya B, Haranath PS. Effects of insulin administered into cerebrospinal fluid spaces on blood glucose in unanaesthetized and anaesthetized dogs. Indian J Med Res 1982; 75: 607-15.
115. Burks DJ, Font de Mora J, Schubert M, et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 2000; 407(6802): 377-82.
116. Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007; 317(5836): 369-72.
117. Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003; 28(6): 809-22.
118. Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 1996; 17(1): 123-30.
119. Stohr O, Hahn J, Moll L, et al. Insulin receptor substrate-1 and -2 mediate resistance to glucose-induced caspase-3 activation in human neuroblastoma cells. Biochim Biophys Acta 2011; 1812(5): 573-80.
120. Hennige AM, Ozcan U, Okada T, et al. Alterations in growth and apoptosis of insulin receptor substrate-1-deficient beta-cells. Am J Physiol Endocrinol Metab 2005; 289(2): E337-46.
121. Jan YN, Jan LY. The control of dendrite development. Neuron 2003; 40(2): 229-42.
122. Goldberg JL. Intrinsic neuronal regulation of axon and dendrite growth. Curr Opin Neurobiol 2004; 14(5): 551-7.
123. Polleux F, Ince-Dunn G, Ghosh A. Transcriptional regulation of vertebrate axon guidance and synapse formation. Nat Rev Neurosci 2007; 8(5): 331-40.
124. de la Torre-Ubieta L, Gaudilliere B, Yang Y, et al. A FOXO-Pak1 transcriptional pathway controls neuronal polarity. Genes Dev 2010; 24(8): 799-813.
125. Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1999; 1(5): 253-9.
126. Wittmann T, Bokoch GM, Waterman-Storer CM. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem 2004; 279(7): 6196-203.
127. Hayashi ML, Choi SY, Rao BS, et al. Altered cortical synaptic morphology and impaired memory consolidation in forebrainspecific dominant-negative PAK transgenic mice. Neuron 2004; 42(5): 773-87.
128. Nikolic M. The Pak1 kinase: an important regulator of neuronal morphology and function in the developing forebrain. Mol Neurobiol 2008; 37(2/3): 187-202.
129. Renault VM, Rafalski VA, Morgan AA, et al. FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell 2009; 5(5): 527-39.
130. Zhang CL, Zou Y, He W, Gage FH, Evans RM. A role for adult TLX-positive neural stem cells in learning and behaviour. Nature 2008; 451(7181): 1004-7.
131. Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F. Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 1995; 14(4): 717-30.
132. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75(1): 59-72.
133. McMorris FA, Smith TM, DeSalvo S, Furlanetto RW. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 1986; 83(3): 822-6.
134. McMorris FA, Dubois-Dalcq M. Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro. J Neurosci Res 1988; 21(2/4): 199-209.
135. Mozell RL, McMorris FA. Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J Neurosci Res 1991; 30(2): 382-90.
136. Altman J, Bayer SA. Migration and distribution of two populations of hippocampal granule cell precursors during the perinatal and postnatal periods. J Comp Neurol 1990; 301(3): 365-81.
137. Morell P, Greenfield S, Costantino-Ceccarini E, Wisniewski H. Changes in the protein composition of mouse brain myelin during development. J Neurochem 1972; 19(11): 2545-54.
138. Matthieu JM, Widmer S, Herschkowitz N. Biochemical changes in mouse brain composition during myelination. Brain Res 1973; 55(2): 391-402.
139. Kappeler L, De Magalhaes Filho C, Dupont J, et al. Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PLoS Biol 2008; 6(10): e254.
140. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38(1): 24-6.
141. Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006; 129(PART 11): 2977-83.
142. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004; 23(1/2): 105-14.
143. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115(6): 1449-57.
144. Kang J, Muller-Hill B. Differential splicing of Alzheimer's disease amyloid A4 precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat and human brain. Biochem Biophys Res Commun 1990; 166(3): 1192-200.
145. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286(5440): 735-41.
146. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM. Protein kinase C-dependent alpha-secretase competes with betasecretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem 2000; 275(4): 2568-75.
147. Walsh DM, Selkoe DJ. A beta oligomers a decade of discovery. J Neurochem 2007; 101(5): 1172-84.
148. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994; 13(1): 45-53.
149. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid betapeptide. Nat Rev Mol Cell Biol 2007; 8(2): 101-12.
150. Tabaton M, Tamagno E. The molecular link between betaand gamma-secretase activity on the amyloid beta precursor protein. Cell Mol Life Sci 2007; 64(17): 2211-8.
151. Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996; 5(7): 985-8.
152. Tanzi RE, Vaula G, Romano DM, et al. Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet 1992; 51(2): 273-82.
153. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258(5082): 668-71.
154. Van Broeckhoven C, Backhovens H, Cruts M, et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet 1992; 2(4): 335-9.
155. St George-Hyslop P, Haines J, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet 1992; 2(4): 330-4.
156. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376(6543): 775-8.
157. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297(5580): 353-6.
158. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403(6765): 98-103.
159. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003; 4(1): 49-60.
160. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006; 314(5800): 781-4.
161. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 1998; 37(31): 11064-77.
162. Crescenzi O, Tomaselli S, Guerrini R, et al. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 2002; 269(22): 5642-8.
163. Zhang S, Iwata K, Lachenmann MJ, et al. The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J Struct Biol 2000; 130(2/3): 130-41.
164. Barrow CJ, Zagorski MG. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 1991; 253(5016): 179-82.
165. Roher AE, Chaney MO, Kuo YM, et al. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996; 271(34): 20631-5.
166. Dahlgren KN, Manelli AM, Stine WB Jr, et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277(35): 32046-53.
167. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46(6): 860-6.
168. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8(1): 79-84.
169. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440(7082): 352-7.
170. Chromy BA, Nowak RJ, Lambert MP, et al. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003; 42(44): 12749-60.
171. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95(11): 6448-53.
172. Klein WL, Stine WB Jr, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 2004; 25(5): 569-80.
173. Georganopoulou DG, Chang L, Nam JM, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2005; 102(7): 2273-6.
174. Harper JD, Wong SS, Lieber CM, Lansbury PT Jr. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 1999; 38(28): 8972-80.
175. Arimon M, Diez-Perez I, Kogan MJ, et al. Fine structure study of Abeta1-42 fibrillogenesis with atomic force microscopy. FASEB J 2005; 19(10): 1344-6.
176. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997; 4(2): 119-25.
177. Kheterpal I, Lashuel HA, Hartley DM, et al. Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry 2003; 42(48): 14092-8.
178. Williams AD, Sega M, Chen M, et al. Structural properties of Abeta protofibrils stabilized by a small molecule. Proc Natl Acad Sci USA 2005; 102(20): 7115-20.
179. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997; 272(35): 22364-72.
180. Ross CA, Poirier MA. Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 2005; 6(11): 891-8.
181. Klunk WE, Jacob RF, Mason RP. Quantifying amyloid by congo red spectral shift assay. Methods Enzymol 1999; 309: 285-305.
182. LeVine H 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999; 309: 274-84.
183. Muller-Hill B, Beyreuther K. Molecular biology of Alzheimer's disease. Annu Rev Biochem 1989; 58: 287-307.
184. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004; 6(11): 1054-61.
185. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8(9): 663-72.
186. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314(5800): 777-81.
187. Hirokawa N, Funakoshi T, Sato-Harada R, Kanai Y. Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. J Cell Biol 1996; 132(4): 667-79.
188. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142(3): 387-97.
189. Gotz J, Ittner LM, Kins S. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? J Neurochem 2006; 98(4): 993-1006.
190. Robertson J, Loviny TL, Goedert M, et al. Phosphorylation of tau by cyclic-AMP-dependent protein kinase. Dementia 1993; 4(5): 256-63.
191. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1992; 147(1): 58-62.
192. Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J Neurosci Res 2000; 62(3): 463-72.
193. Cho JH, Johnson GV. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 2004; 88(2): 349-58.
194. Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005; 1739(2/3): 280-97.
195. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 1996; 17(6): 1201-7.
196. Liu R, Zhou XW, Tanila H, et al. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med 2008; 12(1): 241-57.
197. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999; 24(5): 186-91.
198. Ott A, Stolk RP, Hofman A, et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996; 39(11): 1392-7.
199. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63(7): 1187-1192.
200. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003; 17(1): 27-45.
201. Muller M, Tang MX, Schupf N, et al. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord 2007; 24(3): 185-192.
202. Xu WL, Atti AR, Gatz M, et al. Midlife overweight and obesity increase late-life dementia risk: A population-based twin study. Neurology 2011; 76(18): 1568-1574.
203. Hassing LB, Dahl AK, Thorvaldsson V, et al. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int J Obes (Lond) 2009; 33(8): 893-898.
204. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Luchsinger JA. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66(3): 336-342.
205. Frolich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105(4-5): 423-438.
206. Frolich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann NY Acad Sci 1999; 893: 290-293.
207. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63-80.
208. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 2011; 225(1): 54-62.
209. Hsu AL, Murphy CT, Kenyon C. Regulation of aging and agerelated disease by DAF-16 and heat-shock factor. Science 2003; 300(5622): 1142-1145.
210. Birkenkamp KU, Coffer PJ. Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans 2003; 31(PART 1): 292-297.
211. de la Monte SM, Chen GJ, Rivera E, Wands JR. Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci 2003; 60(12): 2679-2691.
212. Lesort M, Johnson GV. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 2000; 99(2): 305-316.
213. Lesort M, Jope RS, Johnson GV. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem 1999; 72(2): 576-584.
214. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272(31): 19547-19553.
215. Cheng CM, Tseng V, Wang J, et al. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 2005; 146(12): 5086-5091.
216. Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004; 101(9): 3100-3105.
217. Zhao L, Teter B, Morihara T, et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 2004; 24(49): 11120-11126.
218. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004; 43(5): 605-608.
219. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002; 8(12): 1390-1397.
220. Carro E, Trejo JL, Spuch C, et al. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 2006; 27(11): 1618-1631.
221. Lanz TA, Salatto CT, Semproni AR, et al. Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. Biochem Pharmacol 2008; 75(5): 1093-1103.
222. Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulinlike growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA 2008; 105(9): 3438-3442.
223. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18(7): 902-904.
224. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010; 75(13): 1195-1202.
225. van Elderen SG, de Roos A, de Craen AJ, et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 2010; 75(11): 997-1002.
226. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70(6): 440-448.
227. Bell MA, Ball MJ. Morphometric comparison of hippocampal microvasculature in ageing and demented people: diameters and densities. Acta Neuropathol 1981; 53(4): 299-318.
228. Hassler O. Vascular changes in senile brains. A micro-angiographic study. Acta Neuropathol 1965; 5(1): 40-53.
229. Buee L, Hof PR, Bouras C, et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol 1994; 87(5): 469-480.
230. Holmes CS, Hayford JT, Gonzalez JL, Weydert JA. A survey of cognitive functioning at difference glucose levels in diabetic persons. Diabetes Care 1983; 6(2): 180-185.
231. Major RH. The Intranasal Application of Insulin, Experimental and Clinical Experiences. Trans Am Clin Climatol Assoc 1935; 51: 21-27.
232. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29(10): 1326-1334.
233. Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50(1): 164-168.
234. Kern W, Benedict C, Schultes B, et al. Low cerebrospinal fluid insulin levels in obese humans. Diabetologia 2006; 49(11): 2790-2792.
235. Araki W, Kume H, Oda A, Tamaoka A, Kametani F. IGF-1 promotes beta-amyloid production by a secretase-independent mechanism. Biochem Biophys Res Commun 2009; 380(1): 111-114.
236. Pedersen WA, McMillan PJ, Kulstad JJ, et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199(2): 265-273.
237. Escribano L, Simon AM, Perez-Mediavilla A, et al. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009; 379(2): 406-410.
238. Escribano L, Simon AM, Gimeno E, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010; 35(7): 1593-1604.
239. Rodriguez-Rivera J, Denner L, Dineley KT. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral glucoregulatory status. Behav Brain Res 2011; 216(1): 255-261.
240. O'Reilly JA, Lynch M. Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP/PS1 mice. J Neuroimmune Pharmacol 2012; 7(1): 140-144.
241. Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone Does not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimer's Disease: Two Phase 3 Studies. Curr Alzheimer Res 2011; 8(5): 592-606.
242. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebocontrolled study. Lancet 2009; 374(9701): 1606-1616.